Overall Fundamental outlook

* NATCOPHARM makes the list of companies with the best technicals at present.

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for NATCOPHARM
Revenue projections for NATCOPHARM

NATCOPHARM's revenue projections indicate a decrease from last year's performance, which could lead to investor caution. A fall in revenue is likely to negatively impact the company's profitability, causing concern for shareholders who may view this as a signal of declining financial health.

Financial Ratios:

currentRatio 4.09800
forwardPE 21.80994
debtToEquity 3.01200
earningsGrowth -0.23500
revenueGrowth -0.00600
grossMargins 0.82408
operatingMargins 0.38650
trailingEps 85.94000
forwardEps 38.14545

With a current ratio 4.098, NATCOPHARM demonstrates the ability to service its short-term debt without difficulty. The company's strong cash reserves and current assets ensure that it can meet its liabilities, reflecting financial stability and healthy liquidity.
NATCOPHARM's Forward PE is in an attractive range, meaning its stock price aligns well with earnings and isn't inflated. This creates room for growth, making it a solid investment opportunity for those looking to benefit from potential price appreciation.
NATCOPHARM's low growth in both earnings and revenue indicates potential profit shrinkage. This downward trend could be a sign of weakening financial health, signaling challenges for the company's future profitability.
NATCOPHARM's positive gross and operating margins indicate a profitable and efficient business model. These metrics highlight the company's ability to generate income while controlling operational costs, reflecting strong financial performance.
NATCOPHARM's forward EPS is lower than its trailing EPS, indicating that the company is expected to be less profitable this year. This suggests a potential slowdown in financial performance.

Price projections:

Price projections for NATCOPHARM
Price projections for NATCOPHARM

NATCO Pharma Limited's price has often been near the lower end of the projected range. This ongoing trend suggests that investor confidence might be waning, and the stock could face challenges in gaining upward momentum.

Insider Transactions:

Insider Transactions for NATCOPHARM
Insider Transactions for NATCOPHARM


There were 4 transactions selling NATCO Pharma Limited stock, with prevailing market price of 829.5124969482422.There were 2 transactions to buy NATCOPHARM stock, with market price of 851.625.The insider transaction records do not exhibit a strong trend, leaving the company’s future direction unclear based on this data alone.

Recommendation changes over time:

Recommendations trend for NATCOPHARM
Recommendations trend for NATCOPHARM


NATCOPHARM has received a mixed set of ratings from analysts, with no clear buy or sell recommendations. This ambiguity points to an uncertain market outlook, prompting investors to seek out other financial indicators to guide their investment strategies.